PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics
plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting
from its next generation SPEAR T-cell targeting MAGE-A4. This next generation SPEAR T-cell, known as ADP-A2M4CD8, expresses the
CD8α co-receptor alongside the engineered TCR that targets MAGE-A4.
Co-expression of CD8α is anticipated to broaden the immune response against solid tumors and increase antitumor activity by
converting CD4+ helper cells into CD8+ killer or cytotoxic T-cells. The preclinical data demonstrate that the
addition of CD8a with the engineered TCR in vitro improved engagement and function in CD4+ T-cells that may support
clonal expansion of CD8+ T-cells, differentiation into effector and memory T-cells, as well as engage the wider immune
system in antitumor responses.
“Our next generation programs are designed to enhance our existing SPEAR T-cells, to improve their ability to target and kill
solid tumors. The preclinical data we presented at AACR indicate that adding CD8a to our ADP-A2M4 candidate may help broaden the
antitumor immune response against additional tumor antigens. Further, the CD8a co-receptor may enhance the ability of
CD4+ SPEAR T-cells to kill cancer cells through the engineered TCR targeting MAGE-A4,” said Rafael Amado, Adaptimmune’s
President of Research & Development.
Poster presentation details:
- Title: Enhanced activity of second-generation MAGE-A4 SPEAR T-cells through co-expression of a CD8α
homodimer
- Session Title: Adoptive Cell Therapy 2
- Session Date and Time: Monday Apr 1, 2019 1:00 PM - 5:00 PM ET
- Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 22
- Poster Board Number: 12
- Abstract Number: 2313
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The
Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target
and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting
MAGE-A4, MAGE-A10, and AFP across multiple solid tumor indications. The Company is located in Philadelphia, USA and Oxfordshire and
Stevenage, UK. For more information, please visit http://www.adaptimmune.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our
actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the
success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and
uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as
well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and
Exchange Commission (SEC) on February 27, 2019, and our other SEC filings. The forward-looking statements contained in
this press release speak only as of the date the statements were made and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez – VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. – Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com